Harrow, Inc. (NASDAQ:HROW – Get Free Report)’s stock price traded down 4.9% during mid-day trading on Wednesday . The company traded as low as $34.59 and last traded at $34.35. 202,454 shares were traded during mid-day trading, a decline of 32% from the average session volume of 295,937 shares. The stock had previously closed at $36.10.
Analyst Ratings Changes
HROW has been the topic of several analyst reports. B. Riley dropped their target price on Harrow from $73.00 to $69.00 and set a “buy” rating on the stock in a report on Wednesday, December 4th. Craig Hallum boosted their target price on shares of Harrow from $45.00 to $65.00 and gave the stock a “buy” rating in a report on Friday, October 4th. Finally, Lake Street Capital upped their price target on shares of Harrow from $45.00 to $55.00 and gave the stock a “buy” rating in a research report on Friday, October 4th.
Get Our Latest Research Report on HROW
Harrow Price Performance
Institutional Investors Weigh In On Harrow
A number of institutional investors have recently made changes to their positions in HROW. Quest Partners LLC acquired a new position in Harrow in the 3rd quarter valued at $29,000. Mirae Asset Global Investments Co. Ltd. raised its stake in Harrow by 21.5% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,283 shares of the company’s stock worth $57,000 after purchasing an additional 227 shares in the last quarter. Hills Bank & Trust Co bought a new stake in Harrow in the 3rd quarter valued at about $107,000. Huntington National Bank acquired a new position in shares of Harrow during the 3rd quarter worth approximately $164,000. Finally, Clarus Group Inc. bought a new position in shares of Harrow during the third quarter worth approximately $225,000. Institutional investors own 72.76% of the company’s stock.
About Harrow
Harrow, Inc operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business. The company was formerly known as Imprimis Pharmaceuticals, Inc and changed its name to Harrow Health, Inc in December 2018. Harrow Health, Inc was incorporated in 2006 and is headquartered in Nashville, Tennessee.
See Also
- Five stocks we like better than Harrow
- What is the Dogs of the Dow Strategy? Overview and Examples
- Why Energy Transfer Stock Could Soar to New Highs in 2025
- NYSE Stocks Give Investors a Variety of Quality OptionsĀ
- 3 Buy-and-Hold Stocks for Long-Term Growth
- Are Penny Stocks a Good Fit for Your Portfolio?
- Despite Short-Term Risks Freeport McMoran Worth a Look
Receive News & Ratings for Harrow Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Harrow and related companies with MarketBeat.com's FREE daily email newsletter.